ArticleCancer cell international2025
Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structural insights into antibody responses against influenza A virus in its natural reservoir.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy originating from precursors of plasmacytoid dendritic cells. This study aimed to understand the relationship between malignant clones in different tissues and determine new biomarkers to improve the management of BPDCN.
methodsWe conducted a comprehensive analysis by integrating single-cell transcriptomic data from bone marrow (BM)-derived cells, peripheral blood mononuclear cells (PBMCs), and skin-derived cells from one BPDCN patient and matched healthy controls (HCs). Validation was performed in two independent cohorts consisting of 12 BPDCN patients and control groups, including common skin tumors, cutaneous lymphomas, inflammatory skin diseases and HCs.
resultsOur study revealed that malignant cells in the skin exhibited greater maturity and differentiation compared with those from BMs, suggesting that the BM is a more likely origin for BPDCN. Additionally, malignant cells across different tissues in the BPDCN patient displayed significant transcriptional heterogeneity. The multiplex immunohistochemistry (mIHC) analysis revealed that the expression of PLD4 was significantly elevated in the dermis of BPDCN patients compared with the control groups. Furthermore, most PLD4-positive cells were found to co-localize with CD123 in BPDCN skin lesions.
conclusionsThis study suggested a potential clonal origin of tumor cells, and revealed the transcriptional heterogeneity among malignant cells across different tissues in BPDCN. PLD4 was identified as a specific marker of malignant cells, aiding in the diagnosis of BPDCN and showing potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.